Hazel Melia
Haematology Medical Advisor
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
Adverse event reporting information can be found at the bottom of this page
Summary of product characteristics & Patient information leaflet for Blenrep 70mg/100mg powder for concentrate for solution for infusion
INDICATION
Blenrep is indicated in adults for the treatment of relapsed or refractory multiple myeloma:
Reference
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via the online form gsk.public.reportum.com
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
BLENREP is a registered trademark of the GlaxoSmithKline group of companies.
Get access to exclusive events on the topics that matter to you, free patient resources including patient support materials, demo devices and updates on the latest in HIV/AIDS, respiratory, oncology and vaccines.
PM-IE-BLM-WCNT-260002 | July 2026